| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/15/2006 | US20060127894 Protein associated with cell growth, differentiation, and death |
| 06/15/2006 | US20060127445 Anti-angiogenic compositions and methods of use |
| 06/15/2006 | US20060127423 Organic compounds |
| 06/15/2006 | US20060127420 Paclitaxel composition for the intravesical treatment of bladder tumor and preparation method thereof |
| 06/15/2006 | US20060127419 Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds |
| 06/15/2006 | US20060127405 Specifically recognizing human oculospanin and having cytotoxic activity against cancer cells, cancer therapy |
| 06/15/2006 | US20060127403 Use of antibodies against tumor-associated antigen |
| 06/15/2006 | US20060127402 Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors |
| 06/15/2006 | US20060127392 Antibody for adcc and inducing cytokine production |
| 06/15/2006 | US20060127378 Composition for promoting the proliferation of lactobacillus casei subsp. casei |
| 06/15/2006 | US20060127353 Fat-binding polymers |
| 06/15/2006 | US20060127349 Administering water soluble complex of hypericin and a polyvinylpyrrolidone; diagnosing and treating tumors |
| 06/15/2006 | US20060127319 dosage form of a mixture of drugs, foaming agents and gases, having improved pharmacokinetics; drug delivery systems |
| 06/15/2006 | US20060127310 Amplification of biotin-mediated targeting |
| 06/15/2006 | US20060127307 Devices and compositions containing boron and silicon for use in neutron capture therapy |
| 06/15/2006 | US20060127306 Radioactively labelled amino acid analogues, their preparation and use |
| 06/15/2006 | CA2849147A1 Compositions comprising a taxoid and a benzimidazole carbamate for the treatment of cancer |
| 06/15/2006 | CA2614574A1 Cytotoxic agents comprising new c-2 modified taxanes |
| 06/15/2006 | CA2600898A1 Novel cancer antigen peptide and the use thereof |
| 06/15/2006 | CA2591332A1 Methylene inhibitors of matrix metalloproteinase |
| 06/15/2006 | CA2591297A1 Il-7 variants with reduced immunogenicity |
| 06/15/2006 | CA2590748A1 Aryl amide sphingosine 1-phosphate analogs |
| 06/15/2006 | CA2590196A1 Use of pta peptides for stratification of individuals having cancer |
| 06/15/2006 | CA2589981A1 Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy |
| 06/15/2006 | CA2589828A1 Compositions comprising a taxoid and a benzimidazole carbamate for the treatment of cancer |
| 06/15/2006 | CA2589274A1 Inhibitors of protein kinases |
| 06/15/2006 | CA2589271A1 Urea inhibitors of map kinases |
| 06/15/2006 | CA2589127A1 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors |
| 06/15/2006 | CA2588764A1 Macrocyclic quinazole derivatives and their use as mtki |
| 06/15/2006 | CA2588761A1 2,4(4,6)pyrimidine derivatives |
| 06/15/2006 | CA2588633A1 Novel anthranilic acid derivative or salt thereof |
| 06/15/2006 | CA2588587A1 Cytotoxic agents comprising new taxanes |
| 06/15/2006 | CA2584307A1 Indane amides with antiproliferative activity |
| 06/14/2006 | EP1669358A1 Cytotoxic agents comprising new taxanes |
| 06/14/2006 | EP1669092A1 Preparation for the prophylaxis of restenose |
| 06/14/2006 | EP1669091A2 Therapeutic inhibitor of vascular smooth muscle cells |
| 06/14/2006 | EP1669073A2 Fulvestrant formulation |
| 06/14/2006 | EP1668985A2 Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
| 06/14/2006 | EP1668132A1 Cytokine involved in epithelial-mesenchymal transition |
| 06/14/2006 | EP1668036A2 High-yield method for the production of human antibodies blocking the biological activity of a human cytokine |
| 06/14/2006 | EP1668013A1 Pyrazolopyrrole derivatives as protein kinase inhibitors |
| 06/14/2006 | EP1668006A1 Quinazoline derivatives as antiproliferative agents |
| 06/14/2006 | EP1667996A1 Quinazoline derivatives |
| 06/14/2006 | EP1667992A1 Quinazoline derivatives |
| 06/14/2006 | EP1667991A1 Quinazoline derivatives as tyrosine kinase inhibitors |
| 06/14/2006 | EP1667980A1 1,4-disubstituted isoquinoline derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases |
| 06/14/2006 | EP1667947A1 Methods of 11c -radiolabelling phenothiazine and pheno thiazine-like compounds |
| 06/14/2006 | EP1667731A1 Bispecific oligonucleotide for the treatment of cns malignancies |
| 06/14/2006 | EP1667726A2 Polyacetal drug conjugates as release system |
| 06/14/2006 | EP1667721A2 Combinations of a vegf receptor inhibitor with other therapeutic agents |
| 06/14/2006 | EP1667720A1 Combination of a histone deacetylase inhibitor with a death receptor ligand |
| 06/14/2006 | EP1667719A1 Treatment of gastrointestinal stromal tumors with imatinib and midostaurin |
| 06/14/2006 | EP1667717A2 Therapeutic human anti-mhc class ii antibodies and their uses |
| 06/14/2006 | EP1667716A1 Cytotoxicity mediation of cells evidencing surface expression of cd44 |
| 06/14/2006 | EP1667711A2 Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris) |
| 06/14/2006 | EP1667709A1 Clostridium botulinum c3 exotransferase compositions and methods for treating tumour spreading |
| 06/14/2006 | EP1667692A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist |
| 06/14/2006 | EP1667691A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate |
| 06/14/2006 | EP1667689A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone |
| 06/14/2006 | EP1667684A1 Use of chk1 inhibitors to control cell proliferation |
| 06/14/2006 | EP1667680A2 Combination methods of treating cancer |
| 06/14/2006 | EP1667656A1 Compositions and methods for delivery of biologically active agents |
| 06/14/2006 | EP1667655A1 New use, pharmaceutical preparations as well as a process for their production |
| 06/14/2006 | EP1667528A1 Hippophae rhamnoides compositions for cancer therapy |
| 06/14/2006 | EP1667522A2 Modified oligonucleotides for telomerase inhibition |
| 06/14/2006 | EP1567507B1 1,2,3- triazole amide derivatives as cytokine inhibitors |
| 06/14/2006 | EP1476434B1 Pyridazine derivatives, use of the same as medicaments, pharmaceutical compositions and method for producing the same |
| 06/14/2006 | EP1438076B1 Radiopharmaceutical agent for the treatment of early stage cancer |
| 06/14/2006 | EP1427420B1 Use of a combination comprising 4-pyridylmethylphthalazines for cancer treatment |
| 06/14/2006 | EP1399439B1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases |
| 06/14/2006 | EP1393075A4 Methods of screening and using inhibitors of angiogenesis |
| 06/14/2006 | EP1381373B1 Medical compositions for use in the treatment or prevention of a functional vitamin b12 deficienfcy |
| 06/14/2006 | EP1379650B1 Preferred segments of neural thread protein and methods of using the same |
| 06/14/2006 | EP1341770B1 Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors |
| 06/14/2006 | EP1339683B1 Estrogen receptor modulators |
| 06/14/2006 | EP1309703B1 Kallikrein gene |
| 06/14/2006 | EP1309564B1 Arylethene-sulfonamides, their preparation and their use as endothelin antagonists |
| 06/14/2006 | EP1278825B1 Methods of producing membrane vesicles |
| 06/14/2006 | EP1267851B1 Compositions comprising carotenoids and use thereof for preventing hormone induced adverse effects |
| 06/14/2006 | EP1255558B1 Anti-april antibodies and hybridoma cells |
| 06/14/2006 | EP1214324B1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| 06/14/2006 | EP1165085B1 Phthalazine derivatives for treating inflammatory diseases |
| 06/14/2006 | EP1117423B1 Immortalized human keratinocyte cell line |
| 06/14/2006 | EP1102596B1 Peptide antagonists of zonulin and methods for use of the same |
| 06/14/2006 | EP1097210B1 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain |
| 06/14/2006 | EP1071468B1 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
| 06/14/2006 | EP1032696B1 Vector for tissue-specific replication and gene expression |
| 06/14/2006 | EP1017675B1 Highly lipophilic camptothecin derivatives |
| 06/14/2006 | EP0964869B1 Methods and compositions for the treatment of neoplastic diseases |
| 06/14/2006 | EP0699236B2 Purified mammalian flt3 ligands and agonists and antagonists thereof |
| 06/14/2006 | EP0666868B2 Use of anti-VEGF antibodies for the treatment of cancer |
| 06/14/2006 | DE19941897B4 IL-6 Rezeptor-Protein, Beta-Kette (gp130) des IL-6 Rezeptor-Proteins, für diese Proteine kodierende DNA, davon abgeleitete RNA, Peptid mit den Aminosäuren 771-811 dieser Beta-Kette oder Teilen davon und deren Verwendungen IL-6 receptor protein beta-chain (gp130) of the IL-6 receptor protein, DNA encoding for these proteins, derived RNA, peptide with the amino acids 771-811 of the beta-chain or parts thereof and their uses |
| 06/14/2006 | DE102004059357A1 New antibody (which specifically recognizes human thiamine 1) useful for blocking the binding of human Thy-1 at its ligand or for blocking the interaction of tumor cells or immune cells with endothelial cells |
| 06/14/2006 | CN1788081A Anti cancer target direction adjustable gene-virus and structure method thereof |
| 06/14/2006 | CN1787995A Alpha, omega-dicarboximide derivatives as useful uro-selective alpha1alpha adrenoceptor blockers |
| 06/14/2006 | CN1787838A Antitumor agents comprising a targeting portion and an immune response triggering portion |
| 06/14/2006 | CN1787837A Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| 06/14/2006 | CN1787828A Heterocarpin, a plant-derived protein with anti-cancer properties |
| 06/14/2006 | CN1786021A 12 amino acid analog epi-position of human B cell specificity membrane molecule CD20 and polypeptide epi-position vaccine configurated by said analog epi-position |
| 06/14/2006 | CN1786005A Hetero poly phosphorus vanadate antitumour medicine and its synthesis method |